X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1405) 1405
Publication (82) 82
Dissertation (11) 11
Book Review (9) 9
Book Chapter (4) 4
Conference Proceeding (1) 1
Journal / eJournal (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (953) 953
oncology (908) 908
dose intensity (809) 809
female (740) 740
chemotherapy (689) 689
middle aged (568) 568
aged (526) 526
adult (477) 477
male (471) 471
antineoplastic combined chemotherapy protocols - therapeutic use (395) 395
index medicus (388) 388
dose-intensity (357) 357
cancer (355) 355
antineoplastic combined chemotherapy protocols - adverse effects (289) 289
treatment outcome (278) 278
antineoplastic combined chemotherapy protocols - administration & dosage (223) 223
colony-stimulating factor (217) 217
drug administration schedule (216) 216
dose-response relationship, drug (211) 211
breast cancer (203) 203
retrospective studies (200) 200
survival (193) 193
cyclophosphamide (192) 192
breast neoplasms - drug therapy (184) 184
cyclophosphamide - administration & dosage (172) 172
doxorubicin - administration & dosage (172) 172
adjuvant chemotherapy (170) 170
neutropenia (169) 169
febrile neutropenia (166) 166
hematology (166) 166
neutropenia - chemically induced (165) 165
aged, 80 and over (162) 162
breast-cancer (158) 158
cisplatin (157) 157
therapy (153) 153
carcinoma (150) 150
non-hodgkins-lymphoma (141) 141
relative dose intensity (139) 139
doxorubicin (138) 138
prognosis (138) 138
survival analysis (138) 138
disease-free survival (135) 135
antineoplastic agents - adverse effects (133) 133
trial (132) 132
granulocyte colony-stimulating factor - therapeutic use (130) 130
medicine & public health (129) 129
cisplatin - administration & dosage (126) 126
neoplasm staging (125) 125
risk factors (121) 121
survival rate (118) 118
care and treatment (116) 116
lung neoplasms - drug therapy (114) 114
pharmacology & pharmacy (114) 114
toxicity (114) 114
adolescent (112) 112
neoplasms - drug therapy (105) 105
antineoplastic agents - administration & dosage (103) 103
vincristine - administration & dosage (103) 103
analysis (101) 101
antineoplastic agents - therapeutic use (99) 99
carboplatin (99) 99
chemotherapy, adjuvant (97) 97
combined modality therapy (91) 91
filgrastim (89) 89
elderly-patients (88) 88
fluorouracil - administration & dosage (86) 86
etoposide - administration & dosage (85) 85
ovarian neoplasms - drug therapy (85) 85
breast neoplasms - pathology (84) 84
combination chemotherapy (84) 84
granulocyte colony-stimulating factor (84) 84
prospective studies (84) 84
randomized trial (83) 83
follow-up studies (81) 81
health aspects (81) 81
fluorouracil (79) 79
cell lung-cancer (78) 78
granulocyte colony-stimulating factor - administration & dosage (77) 77
lymphoma, non-hodgkin - drug therapy (77) 77
ovarian cancer (76) 76
research (74) 74
lymphoma (73) 73
paclitaxel (72) 72
mortality (71) 71
doxorubicin - adverse effects (70) 70
etoposide (70) 70
neutropenia - prevention & control (70) 70
cyclophosphamide - adverse effects (69) 69
methotrexate (68) 68
prednisone - administration & dosage (68) 68
randomized-trial (65) 65
recombinant proteins (64) 64
phase-ii (63) 63
g-csf (62) 62
carboplatin - administration & dosage (60) 60
time factors (60) 60
hematology, oncology and palliative medicine (59) 59
lymphomas (59) 59
pegfilgrastim (59) 59
methotrexate - administration & dosage (58) 58
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1298) 1298
French (38) 38
Chinese (23) 23
German (21) 21
Japanese (19) 19
Spanish (8) 8
Italian (6) 6
Polish (3) 3
Russian (3) 3
Czech (1) 1
Hungarian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Summated Chemotherapy Dose-intensity versus Loco-regional Response in Locally Advanced Breast Cancer: Its Possible Implications, 12/2003
Background: Summated dose-intensity (SDI) of chemotherapy regimen could influence the outcome in malignancies. Aims: To evaluate the implication of SDI and... 
Dose-intensity, Dose-response, Locally advanced breast cancer, Neoadjuvant chemotherapy
Journal
by Sasaki and Fukushima and Haraguchi and Miuma and Miyaaki and Hidaka and Eguchi and Matsuo and Tajima and Matsuzaki and Hashimoto and Ooba and Kugiyama and Yatsuhashi and Motoyoshi and Shigeno and Kinoshita and Nakao
Cancers, ISSN 2072-6694, 11/2019, Volume 11, Issue 11, p. 1769
Background: Lenvatinib is currently available as the first-line treatment for advanced unresectable hepatocellular carcinoma. We evaluated the relationship... 
lenvatinib | relative dose intensity | hepatocellular carcinoma
Journal Article
Journal Article
Haematologica, ISSN 0390-6078, 03/2018, Volume 103, Issue 4, pp. e169 - e172
Journal Article
Bulletin du Cancer, ISSN 0007-4551, 09/2017, Volume 104, Issue 9, pp. 714 - 720
Introduction Chemotherapy induced toxicities can generate changes in prescribing and relative dose intensity which have an impact on therapeutic efficacy.... 
Prescription | Chemotherapy | Dose intensity | Colorectal | Toxicity
Journal Article
by Wang and Tsuchiya and Kurosaki and Yasui and Inada and Kirino and Yamashita and Sekiguchi and Hayakawa and Osawa and Okada and Higuchi and Takaura and Maeyashiki and Kaneko and Tamaki and Nakanishi and Itakura and Takahashi and Asahina and Enomoto and Izumi
Cancers, ISSN 2072-6694, 10/2019, Volume 11, Issue 10, p. 1517
Background: We aimed to explore the relative dose intensity (RDI) and post-regorafenib treatments in regorafenib therapy. Methods: The medical records of 38... 
sequential therapy | relative dose intensity (rdi) | regorafenib | sorafenib | hepatocellular carcinoma
Journal Article
ONCOLOGY RESEARCH AND TREATMENT, ISSN 2296-5270, 2019, Volume 42, Issue 1-2, pp. 69 - 69
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 11/2012, Volume 30, Issue 33, pp. 4148 - 4154
Journal Article
ANTICANCER RESEARCH, ISSN 0250-7005, 09/2019, Volume 39, Issue 9, pp. 5149 - 5156
Background: Factors associated with response to lenvatinib have not been clarified in patients with hepatocellular carcinoma (HCC). Patients and Methods: This... 
objective response | SURVIVAL | lenvatinib | ONCOLOGY | FATIGUE | Hepatocellular carcinoma | dose intensity | SORAFENIB | MRECIST | Liver cancer | Solid tumors | Multivariate analysis | Tumors
Journal Article
Leukemia and Lymphoma, ISSN 1042-8194, 01/2019, Volume 60, Issue 1, pp. 172 - 179
The pivotal LYM-3002 study compared frontline rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) with bortezomib, rituximab,... 
VR-CAP | dose intensity | bortezomib | R-CHOP | LYM-3002 | Mantle cell lymphoma | MULTIPLE-MYELOMA | GUIDELINES | CHEMOTHERAPY | THERAPY | ONCOLOGY | RITUXIMAB | HEMATOLOGY
Journal Article
Journal Article
CANCER, ISSN 0008-543X, 12/2017, Volume 123, Issue 24, pp. 4868 - 4877
BACKGROUNDFor many chemotherapy regimens dosed based on body surface area (BSA), patients experience dose reductions or delays or discontinue treatment,... 
SURVIVAL | colon cancer | BODY-SURFACE AREA | relative dose intensity | TOXICITY | chemotherapy | skeletal muscle mass | SKELETAL-MUSCLE | body composition | OBESITY | IMPACT | INDEPENDENT DETERMINANT | dose-limiting toxicity | ONCOLOGY | NUTRITIONAL-STATUS | OUTCOMES | INDEX | body surface area
Journal Article
Leukemia & lymphoma, ISSN 1042-8194, 8/2015, Volume 56, Issue 8, pp. 2365 - 2372
The optimal treatment of follicular lymphoma (FL) is not established. Rituximab is an important component of FL treatment making the impact of chemotherapy on... 
Immunochemotherapy | Follicular Lymphoma | dose intensity | Treatment delivery
Journal Article
Frontiers in pharmacology, ISSN 1663-9812, 2019, Volume 10, p. 481
Chemotherapy-induced hematologic toxicity is the primary reasons of dose reductions and/or delays, low relative dose intensity (RDI), and predicts anticancer... 
CYP2J2 | CYP2C9 | breast cancer | hematologic toxicity | chemotherapy | reduced relative dose intensity
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 10/2007, Volume 357, Issue 15, pp. 1496 - 1506
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.